Geneva, Switzerland
European Academy of Neurology (EAN 2026)
June 27 - 30, 2026
Myasthenia Gravis (MG)
MG is a rare, chronic autoimmune disease affecting the neuromuscular junction.
This results in fluctuating, fatigable weakness of the skeletal muscles.1-2 Symptoms can affect numerous systems in the body, such as ocular, pulmonary, and urinary.1-4 Most patients suffer with feelings of fatigue, anxiety and depression which impairs their ability to live a normal life.4-5
Upcoming Myasthenia Gravis Medical Congress Events
Our Latest Myasthenia Gravis Publications
Efficacy and Safety of Telitacicept in Patients with Generalized Myasthenia Gravis: Results of a Phase 3 Study
Efficacy and Safety of Telitacicept in Patients with Generalized Myasthenia Gravis: Results from a Phase 3 Study
Global Phase 3 Study to Evaluate the Efficacy and Safety of Telitacicept in Patients With Generalized Myasthenia Gravis (RemeMG)
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study With an Open-label Extension Period to Evaluate the Efficacy and Safety of Telitacicept in Patients With Generalized Myasthenia Gravis (UPSTREAM MG)
A Phase 3 Study to Evaluate the Efficacy and Safety of Telitacicept in Patients With Generalized Myasthenia Gravis: Trial Design Update
References:
- Juel VC. Continuum (Minneap Minn). 2025;31(5):1270-1302.
- Dresser L, et al. J Clin Med. 2021;10(11):2235. 4. Pesa J, et al. BMC Neurol. 2024;24(1):384.
- Shihada K, et al. Neurol Sci. 2026;47(1):91
- Jackson K, et al. Neurol Ther. 2023;12(1):107-128
- Richards HS, et al. Eye (Lond). 2014;28(3):296-302